Helicos BioSciences

Helicos BioSciences is a biotechnology firm specializing in advanced sequencing technologies, particularly in RNA and DNA sequencing. Their innovative solutions aim to facilitate genomic research and personalized medicine, enhancing accuracy and efficiency in molecular biology studies. Helicos BioSciences, headquartered in Cambridge, US, focuses on developing sequencing technologies that eliminate the need for library preparation or amplification in RNA and DNA sequencing. The company pivoted to an IPO on May 24, 2007, with UBS Investment Bank as the sole book-running manager.

The founder's history and previous ventures are not detailed in the available information. The company has successfully raised a total of USD 18. 60 mn through funding, with the latest round in May 2007 involving notable investors such as Atlas Venture, Flagship Pioneering, Highland Capital Partners, RS Investment Partners, Versant Ventures, and Vision Capital Advisors. Helicos BioSciences specializes in True Single Molecule Sequencing (tSMS), enabling direct RNA and DNA sequencing without library preparation.

This technology provides high accuracy by reducing errors associated with conventional methods. Their services cater to diverse clients, including academic institutions, biotech firms, and healthcare organizations focused on genomic research and personalized medicine, particularly beneficial for analyzing gene expression and handling degraded samples. In the most recent fiscal year, Helicos BioSciences reported revenue of USD 3,230,000 and an EBITDA of USD -6,038,000. The company's revenue model is based on providing sequencing services to clients such as universities and pharmaceutical companies, featuring tailored pricing plans that may include volume discounts for larger projects.

Helicos BioSciences plans to leverage its recent funding of USD 18. 60 mn to expand its product offerings and enhance its sequencing technologies. The company is targeting new geographic markets, with specific plans to increase its presence in Europe and Asia by the end of 2008. The funds raised will support the development of new sequencing products and the scaling of operations to meet growing demand in genomic research.